Overall, increasing our pharmacological knowledge of BKCa channel activators and inhibitors and their role(s) in modulating different forms of epilepsy, and other diseases of hyperexcitability, and of how different BK heteromonomers and/or heteromultimers may be targeted selectively, is a key aim. This evidence concerns the gene KNG1 and epilepsy.